BioSpace News Archive

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they received a $2.9 million grant from the National Institutes of Health.

Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced that clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, will be presented on four posters at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Vincerx Pharma, Inc. announced that it will present three posters related to VIP943, VIP924, and enitociclib at the 65th American Society for Hematology Meeting, taking place in San Diego California from December 9 to 12, 2023.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma, at the 65th American Society of Hematology Annual Meeting & Exposition, which is taking place in-person and virtually from December 9-12, 2023.

Scopus BioPharma Inc. and its subsidiary, Duet BioTherapeutics Inc. announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer.

Harpoon Therapeutics, Inc. announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma.

Centessa Pharmaceuticals plc announced that new data from an additional 52-weeks of continuous treatment from the third year of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during a poster session at the 65th American Society of Hematology Annual Meeting in San Diego, CA on December 10, 2023.

Editas Medicine, Inc. announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and from the EdiTHAL trial of EDIT-301 in patients with transfusion-dependent beta thalassemia has been accepted for a poster presentation at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA, and online.

Inhibrx, Inc. announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide for the treatment of advanced or metastatic, unresectable Ewing sarcoma.

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies, shares new highlights from the BASECAMP-1 ( NCT04981119 ) master pre-screening protocol in an oral presentation Friday, November 3, at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego.